ArticleClinical pharmacology : advances and applications2013
Advances in the management of glioblastoma: the role of temozolomide and MGMT testing.
Article in Clinical pharmacology : advances and applications, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.
- O-6-Methylguanine-DNA methyltransferase expression is associated with pituitary adenoma tumor recurrence: a systematic meta-analysis.Oncotarget · 2017Pooled it
- The evolution of chemotherapy in brain tumors: from historical milestones to precision medicine in glioblastoma.Exploration of targeted anti-tumor therapy · 2026Review
- The Temozolomide-Doxorubicin paradox in Glioblastoma in vitro-in silico preclinical drug-screening.Scientific reports · 2024Article
- Molecular Pathways Implicated in Radioresistance of Glioblastoma Multiforme: What Is the Role of Extracellular Vesicles?International journal of molecular sciences · 2023Review
- Glioblastoma Multiforme: Probing Solutions to Systemic Toxicity towards High-Dose Chemotherapy and Inflammatory Influence in Resistance against Temozolomide.Pharmaceutics · 2023Article
- Mixed malignant glioblastoma and schwannoma in spinal cord with metachronous ependymoma: A case report.Clinical case reports · 2021Article
- Rehabilitation of Adult Patients with Primary Brain Tumors: A Narrative Review.Brain sciences · 2020Review
- miR-152-5p suppresses glioma progression and tumorigenesis and potentiates temozolomide sensitivity by targeting FBXL7.Journal of cellular and molecular medicine · 2020Article
- Disparity between Inter-Patient Molecular Heterogeneity and Repertoires of Target Drugs Used for Different Types of Cancer in Clinical Oncology.International journal of molecular sciences · 2020Article
- GARP as an Immune Regulatory Molecule in the Tumor Microenvironment of Glioblastoma Multiforme.International journal of molecular sciences · 2019Article
- Temozolomide and tranilast synergistic antiproliferative effect on human glioblastoma multiforme cell line (U87MG).Medical journal of the Islamic Republic of Iran · 2019Article
- NK Cell-Based Glioblastoma Immunotherapy.Cancers · 2018Review
- Efficacy of arginine depletion by ADI-PEG20 in an intracranial model of GBM.Cell death & disease · 2018Article
- Tunable Stability of Imidazotetrazines Leads to a Potent Compound for Glioblastoma.ACS chemical biology · 2018Article
- Article
- Aptamers and Glioblastoma: Their Potential Use for Imaging and Therapeutic Applications.International journal of molecular sciences · 2017Review
- On glioblastoma and the search for a cure: where do we stand?Cellular and molecular life sciences : CMLS · 2017Review
- Temozolomide in the Era of Precision Medicine.Cancer research · 2017Review
- Preparation of Temozolomide-Loaded Nanoparticles for Glioblastoma Multiforme Targeting-Ideal Versus Reality.Pharmaceuticals (Basel, Switzerland) · 2016Article
- Effects of temozolomide (TMZ) on the expression and interaction of heat shock proteins (HSPs) and DNA repair proteins in human malignant glioma cells.Cell stress & chaperones · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma (GB) is one of the most lethal forms of cancer, with an invasive growth pattern that requires the use of adjuvant therapies, including chemotherapy and radiation, to prolong survival. Temozolomide (TMZ) is an oral chemotherapy with a limited side effect profile that has become the standard of care in GB treatment. While TMZ has made an impact on survival, tumor recurrence and TMZ resistance remain major challenges. Molecular markers, such as O6-methylguanine-DNA methyltransferase methylation status, can be helpful in predicting tumor response to TMZ, and therefore guides clinical decision making. This review will discuss the epidemiology and possible genetic underpinnings of GB, how TMZ became the standard of care for GB patients, the pharmacology of TMZ, the practical aspects of using TMZ in clinic, and how molecular diagnostics - particularly the use of O6-methylguanine-DNA methyltransferase status - affect clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.